Edit |   |
Antigenic Specificity | PIAS2 (PIASx1/2) (C-term), 518-547 |
Clone | polyclonal |
Host Species | Rabbit |
Reactive Species | human (predicted reactivity: rat) |
Isotype | n/a |
Format | purified |
Size | 0.08 mL, 0.4 mL |
Concentration | vial concentration: 1.36 |
Applications | ELISA (EIA), Immunohistochemistry (IHC) |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | This PIAS2 (PIASx1/2) antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 518-547 amino acids from the C-terminal region of human PIAS2 (PIASx1/2). PIASX functions as an E3-type small ubiquitin-like modifier (SUMO) ligase, stabilizing the interaction between UBE2I and the substrate, and as a SUMO-tethering factor. This protein plays a crucial role as a transcriptional coregulator in various cellular pathways, including the STAT pathway, the p53 pathway and the steroid hormone signaling pathway. The effects of this transcriptional coregulation, transactivation or silencing may vary depending upon the biological context and the PIAS2 isoform studied. However, it seems to be mostly involved in gene sile |
Immunogen | n/a |
Other Names | [E3 SUMO-protein ligase PIAS2; 632-; Androgen receptor-interacting protein 3; ARIP3; DAB2-interacting protein; DIP; Msx-interacting zinc finger protein; Miz1; PIAS-NY protein; Protein inhibitor of activated STAT x; Protein inhibitor of activated STAT2; PIAS2; PIASX] |
Gene, Accession # | [PIAS2], Gene ID: 9063, NCBI: NP_004662.2, UniProt: O75928 |
Catalog # | MBS9212470 |
Price | $165, $370 |
Order / More Info | PIAS2 (PIASx1/2) (C-term), 518-547 Antibody from MYBIOSOURCE INC. |
Product Specific References | Sakurai, T., et al., J. Biol. Chem. 279(15):15505-15514 (2004). Arora, T., et al., J. Biol. Chem. 278(24):21327-21330 (2003). Wu, S., et al., Oncogene 22(3):351-360 (2003). Liu, B., et al., Proc. Natl. Acad. Sci. U.S.A. 95(18):10626-10631 (1998). Wu, L., et al., Mech. Dev. 65 (1-2), 3-17 (1997). |